Virus Vaccine Solutions Inc. Statement of comprehensive income For the year ended December 31, 2020 (in '000s) Sales revenue $4,600 Cost of goods sold 1,840 Gross profit 2,760 Sales, general and administrative expenses 855 Interest expense 61 Depreciation and amortization expense 194 1,650 Other income 650 Earnings before income tax expense 2,300 Income tax expense 920 Net income $ 1,380 Required: a) Use the acquisition method to allocate the acquisition differential and determine goodwill arising on acquisition, assuming that VVS uses the identifiable net assets (INA) method to value the non-controlling interest (NCI). (5 marks) b) Use the acquisition method to allocate the acquisition differential and determine goodwill arising on acquisition, assuming that VVS uses the fair value enterprise (FVE) method to value the NCI. (5 marks) For all remaining parts of the question assume that VVS uses the FVE method. c) Prepare an acquisition differential and impairment schedule for 2020. Provide references for each line in the AD schedule that will be used to reference through to the consolidated financial statements. (10 marks) d) Prepare a list of all intercompany transactions and balances that are pertinent to the case facts and should be eliminated upon consolidation. (4 marks) ) Calculate all unrealized and realized intercompany profits. Include a calculation of the total deferred tax asset/liability. (12 marks) f) Prepare VVS's consolidated statement of comprehensive income for the year ended December 31, 2020. Show the allocation between the parent and the NCI. (18 marks)